PMID- 11465317
OWN - NLM
STAT- MEDLINE
DCOM- 20010920
LR  - 20131121
IS  - 0037-5675 (Print)
IS  - 0037-5675 (Linking)
VI  - 42
IP  - 4
DP  - 2001 Apr
TI  - Risperidone in the treatment of first episode psychosis.
PG  - 170-3
AB  - OBJECTIVE: To evaluate the efficacy and safety of risperidone in Singapore 
      patients with first-episode psychosis in an eight-week open label prospective 
      study. METHOD: Previously untreated male and female patients aged 18 - 65 with 
      DSM IV schizophreniform disorder or DSM IV schizophrenia for no longer than 12 
      months were recruited from Woodbridge Hospital and Geylang Psychiatric Outpatient 
      Clinic. Patients were treated with risperidone for 56 days. Outcome was assessed 
      with the Positive and Negative Syndrome Scale (PANSS), the Clinical Global 
      Impression scale (CGI). Safety was assessed by monitoring of vital signs and by 
      comparing the frequency of adverse events (AEs) before and after treatment. 
      RESULTS: 24 patients with a mean age of 33.29+/-9.12 years and a mean duration of 
      illness of 166.5+/-111.4 days (median 180 days) were included. The mean 
      risperidone dosage was 2.7 mg +/- 1.0 at day 56. Mean PANSS total scores reduced 
      by 50.21% from 88.29+/-21.55 at baseline to 43.96+/-7.5 at endpoint (p < 0.001). 
      The responder rate (> or = 20% reduction in the total PANSS score) was 87.5%. 13 
      patients (54.2%) exhibited a 50% or greater reduction in total PANSS score. 
      Except for item G5 (mannerisms and posturing) all single PANSS items were reduced 
      significantly. The CGI scores of all patients improved at endpoint. No serious 
      adverse events were reported. CONCLUSIONS: Overall the therapy of first-episode 
      psychosis patients with risperidone was effective and safe.
FAU - Yap, H L
AU  - Yap HL
AD  - Woodbridge Hospital & Institute of Mental Health, Singapore.
FAU - Mahendran, R
AU  - Mahendran R
FAU - Lim, D
AU  - Lim D
FAU - Liow, P H
AU  - Liow PH
FAU - Lee, A
AU  - Lee A
FAU - Phang, S
AU  - Phang S
FAU - Tiong, A
AU  - Tiong A
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - India
TA  - Singapore Med J
JT  - Singapore medical journal
JID - 0404516
RN  - 0 (Antipsychotic Agents)
RN  - L6UH7ZF8HC (Risperidone)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/adverse effects/*therapeutic use
MH  - Clinical Trials, Phase IV as Topic
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Psychotic Disorders/*drug therapy
MH  - Risperidone/adverse effects/*therapeutic use
MH  - Statistics, Nonparametric
EDAT- 2001/07/24 10:00
MHDA- 2001/09/21 10:01
CRDT- 2001/07/24 10:00
PHST- 2001/07/24 10:00 [pubmed]
PHST- 2001/09/21 10:01 [medline]
PHST- 2001/07/24 10:00 [entrez]
PST - ppublish
SO  - Singapore Med J. 2001 Apr;42(4):170-3.